

RESEARCH NOTE

Long-term quality-of-life impairment in patients with more than 1-year COVID-19–related olfactory dysfunction

Alfonso Luca Pendolino MD^{1,2}  | Hui Qi Mandy Tan MS³ | David Choi PhD⁴ |
Giancarlo Ottaviano PhD⁵  | Peter J Andrews MDRes^{1,2}

¹Department of ENT, Royal National ENT & Eastman Dental Hospitals, London, UK

²Ear Institute, University College London, London, UK

³University College London, Medical School, London, UK

⁴Department of Neurosurgery, National Hospital for Neurology and Neurosurgery, London, UK

⁵Department of Neurosciences, Otolaryngology Section, University of Padova, Padova, Italy

Correspondence

Mr Alfonso Luca Pendolino, MD, Department of ENT, Royal National Ent & Eastman Dental Hospitals, London, 47-49 Huntley St, Bloomsbury, London WC1E 6DG, UK.

Email: alfonso.pendolino@nhs.net

KEYWORDS

olfaction, olfactory disorders, olfactory test, quality of life, SNOT-22

1 | INTRODUCTION

Olfactory dysfunction (OD) impacts patients' lives, and the causes for this are multiple.¹ It results in decreased flavor perception, and the inability to recognize spoiled food, hazardous odors, or volatile chemicals poses a health and safety risk. Compared with other causes of olfactory disorders, postinfectious OD is associated with a higher level of quality of life (QoL) impairment. Pre–coronavirus disease 2019 (COVID-19) studies confirmed that QoL is reduced in patients with OD and recent studies show the impact of COVID-19–related OD on patients' QoL both in the short² and medium term.³ To date, its long-term consequences on QoL remain partially unexplored. We investigated by means of Sniffin' Sticks (SS) test and validated QoL questionnaires the effects of persistent COVID-19–related OD on QoL in patients with a history of OD longer than 1 year.

2 | METHODS

We conducted a cross-sectional study including patients with a history of mild to moderate COVID-19 referred to our long-COVID smell clinic between December 2020 and April 2022 for persistent COVID-19–related OD. Patients with a preexisting history of OD or other pathologies known to affect olfaction were not included. The study was conducted in accordance with the 1996 Declaration of Helsinki and approved by the research ethics committee (reference 14/SC/1180).

Detailed characteristics of the population are reported in Table 1. Olfaction was assessed using the SS extended test, while self-assessment of smell was performed using a visual analog scale (sVAS).⁴ The 36-Item Short Form Health Survey (SF-36) was chosen for the measurement of QoL, while the brief version of the Questionnaire of Olfactory Disorders-Negative Statements (brief QOD-NS)⁵

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. *International Forum of Allergy & Rhinology* published by Wiley Periodicals LLC on behalf of American Academy of Otolaryngic Allergy and American Rhinologic Society.

TABLE 1 Detailed characteristics and differences in olfaction and questionnaires scores for normosmic and dysosmic patients

	Normosmia (n = 14)	Dysosmia (n = 46)	p Value
General characteristics			
Age (mean ± SD) (years)	44.4 ± 12.3	43.0 ± 13.1	0.71
Sex, n (%)			
Men	7 (50.0)	13 (28.3)	0.19
Women	7 (50.0)	33 (71.7)	
Duration of smell loss (mean ± SD) (days)	405.4 ± 151.8	431.1 ± 198.5	0.66
Parosmia, n (%)			
No	2 (14.3)	8 (17.4)	>0.99
Yes	12 (85.7)	38 (82.6)	
Phantosmia, n (%)			
No	10 (71.4)	29 (63.0)	0.75
Yes	4 (28.6)	17 (37.0)	
Smoking status, n (%)			
Never smoked	11 (78.6)	38 (82.6)	
Have smoked	3 (21.4)	8 (17.4)	0.71
Current	1 (7.1)	4 (8.7)	
Quit	2 (14.3)	4 (8.7)	
Comorbidities, n (%)			
None	9 (64.3)	33 (71.7)	0.74
Yes	5 (35.7)	13 (28.3)	
Hypothyroidism	2	2	
Hypertension	1	3	
Hyperlipidemia	1	2	
Diabetes	1	2	
Allergic rhinitis	1	1	
Migraine	2	0	
Others	3	15	
Previous nasal operations, n (%)			
No	14 (100.0)	39 (84.8)	0.18
Yes	0 (0)	7 (15.2)	
Rhinitis, n (%)			
No	8 (57.1)	35 (76.1)	0.19
Yes	6 (42.9)	11 (23.9)	
Medication use, n (%)			
None	13 (92.9)	37 (80.4)	0.43
Yes	1 (7.1)	9 (19.6)	
α-Blockers	0	0	
Sartans	0	0	
Dicumarolics	0	0	
Antiplatelet drugs	0	2	
Biguanides	0	0	
Antidepressants	0	2	
Others	1	8	

(Continues)

TABLE 1 (Continued)

	Normosmia (n = 14)	Dysosmia (n = 46)	p Value
Olfactory test and PROMs			
Sniffin' Sticks score (median [IQR])			
TDI	32.0 [31.4 – 33.6]	23.3 [20.4 – 28.3]	<0.0001****
Threshold	6.8 [5.8 – 7.6]	4.6 [1.4 – 5.5]	<0.0001****
Discrimination	14.0 [13.0 – 15.0]	10.0 [8.0 – 12.0]	<0.0001****
Identification	12.0 [11.0 – 13.0]	10.0 [7.8 – 11.0]	0.0002***
SNOT-22 (median [IQR])			
Total SNOT-22 score	16.5 [10.0 – 30.5]	23.0 [12.5 – 46.0]	0.23
Rhinologic symptoms ^a	4.5 [1.0 – 6.0]	2.0 [0 – 5.0]	0.11
Extranasal rhinologic symptoms	0 [0 – 3.0]	0 [0 – 1.0]	0.45
Ear/facial symptoms	0 [0 – 4.3]	1.0 [0 – 4.0]	0.49
Psychological dysfunction	5.0 [1.8 – 10.0]	10.5 [5.0 – 21.3]	0.03*
Sleep dysfunction	4.0 [2.3 – 10.3]	9.5 [1.3 – 16.0]	0.24
Loss of smell or taste	3.0 [2.8 – 4.0]	4.0 [3.0 – 5.0]	0.01**
SF-36 (mean ± SD or median [IQR]) ^b , (%)			
Physical functioning	95.0 [85.0 – 100]	95.0 [80.0 – 100]	0.82
Role limitations because of physical health	100 [100 – 100]	100 [43.8 – 100]	0.11
Role limitations because of emotional problems	100 [66.7 – 100]	66.7 [25.0 – 100]	0.07
Energy/fatigue	67.9 ± 12.7	46.5 ± 18.1	0.0001****
Emotional well-being	77.4 ± 16.4	63.2 ± 18.2	0.01**
Social functioning	84.8 ± 20.3	68.8 ± 28.6	0.05*
Pain	90.0 [67.5 – 92.5]	85.0 [67.5 – 100]	0.80
General health	74.6 ± 12.9	65.2 ± 21.8	0.05*
QOD-NS (mean ± SD)	15.1 ± 4.8	8.5 ± 5.5	0.0001****
sVAS (mean ± SD)	7.5 ± 0.5	3.3 ± 2.2	<0.0001****

Significant *p* values in bold. Levels of significance **p* ≤ 0.05, ***p* ≤ 0.01, ****p* ≤ 0.001, *****p* ≤ 0.0001.

^aThe item “loss of smell or taste” was excluded from the rhinologic symptoms domain and presented separately.

Abbreviations: PROMs, patient-reported outcome measures; QOD-NS, brief version of the Questionnaire of Olfactory Disorders-Negative Statements; SF-36, 36-Item Short Form Health Survey; SNOT-22, Sino-Nasal Outcome Test-22; sVAS, visual analog scale for sense of smell (0 represents “sense of smell absent” and 10 “sense of smell not affected”).

^bResults of mean ± standard deviation (SD) or median [interquartile range (IQR)] have been reported according to data distribution (normal vs non-normal distribution).

was used to quantify the smell loss symptoms' effect on patients' QoL. Sinonasal symptoms were evaluated using the Sino-Nasal Outcome Test-22 (SNOT-22).

Variables were compared using unpaired *t* test and Mann-Whitney test. Fisher exact test was used to investigate associations between variables in normosmic and dysosmic patients. Linear regression analysis was used to explore correlations between odor threshold (T), odor discrimination (D), and odor identification (I) (TDI) scores and questionnaire outcomes.

3 | RESULTS

Sixty patients completed the assessment and were included in the study (Table 1). None of the patients had other

long-haul COVID-19 symptoms apart from OD. Patients were categorized into three groups based on their TDI score: 14 normosmics (patients who reported OD but showed normal SS scores [TDI ≥ 30.75]), 39 hyposmics (16 < TDI < 30.75), and seven anosmics (TDI ≤ 16). For comparative analysis, patients with hyposmia and anosmia were combined and classified as “dysosmics” (*n* = 46).

No differences in the general characteristics and qualitative OD (parosmia/phantosmia) were observed between normosmics and dysosmics. Dysosmics showed significantly lower scores (worse outcomes) in the SF-36 domains “energy/fatigue,” “emotional well-being,” “social functioning,” and “general health,” and brief QOD-NS, sVAS, and SS scores, with threshold being the most affected SS subtest. Similarly, dysosmics had higher scores (worse outcomes) in SNOT-22 subdomains “psychological




FIGURE 1 Results from 36-Item Short Form Health Survey (SF-36) and Sino-Nasal Outcome Test-22 (SNOT-22) radar charts (left) showing median scores for normosmic and dysosmic patients and their p values. Box plots (right) demonstrate SF-36 and SNOT-22 domains with significant differences between the two groups.

dysfunction” and “loss of smell or taste” (Table 1, Figure 1). A significant linear correlation was found between the SS and SF-36 domain “energy/fatigue” ($p < 0.01$ for all but identification, which was not significant) and sVAS ($p = 0.03$ for identification and $p < 0.01$ for the remaining SS scores).

4 | DISCUSSION

Our study offers the longest follow-up (14 months) at which effects of COVID-19-related OD on QoL have been measured. Dysosmic patients demonstrated worse QoL scores when compared with normosmics, especially in the SF-36 domains “energy/fatigue,” “emotional well-being,” and “social functioning,” which confirms the difficulties these patients report in their everyday activities.⁶ However, when we looked at the SF-36 scores of those who recovered their sense of smell (normosmics), these were found

to be within the normative values for the UK population,⁷ suggesting how olfactory recovery could contribute to improving QoL.

Our data highlight a significantly higher psychological dysfunction in dysosmic patients according to SNOT-22 when compared with normosmics, corroborating previous findings demonstrated both in the medium⁸ and long term.⁹ At 14 months from OD onset, dysosmic patients continued to have lower SS scores with a linear correlation demonstrated with the SF-36 domain “energy/fatigue,” which could reflect the general level of debility commonly reported by dysosmic patients. However, both the identification and, more significantly, the threshold scores were found to be outside SS normative values also in the normosmic group. This confirms how threshold remains the most affected task in COVID-19-related OD both in the medium⁴ and long term.⁶

Qualitative disorders (parosmia/phantosmia) have been reported to be more associated with severe reduction in

QoL than purely quantitative disorders, and the fact that QoL in our normosmic group was within the normal range despite a similar rate of parosmia/phantosmia in the two groups may be caused by either a less severe qualitative OD in patients who recovered their sense of smell or the adoption of more efficient compensatory strategies to cope with parosmia.

Dysosmic patients demonstrated lower scores at the brief QOD-NS, confirming its usefulness in discriminating patients at a higher risk of QoL detriments related to OD.¹⁰ A significant linear correlation between sVAS and SS (both TDI and SS subtests scores) was also observed in our analysis, replicating previous results.⁴

A limit of the study is the lack of a control group of patients with no history of OD with or without previous COVID-19. However, we could speculate that our normosmic group offers similar characteristics, whereas QoL scores were found to be within the normal range. Because of the cross-sectional nature of the study and the fact that it included only patients with reported OD, results need to be verified in wider populations.

In conclusion, patients with persistent OD show worse QoL scores than those who have recovered sense of smell, suggesting how olfactory recovery could contribute to QoL improvement. Threshold remains the most affected task in the long term, which strengthens the hypothesis that SARS-CoV-2 targets the olfactory epithelium.

CONFLICT OF INTEREST

The authors declare that they have no conflicts of interest.

ORCID

Alfonso Luca Pendolino MD  <https://orcid.org/0000-0002-6348-5303>

Giancarlo Ottaviano PhD  <https://orcid.org/0000-0003-2433-4761>

REFERENCES

1. Patel ZM, Holbrook EH, Turner JH, et al. International consensus statement on allergy and rhinology: olfaction. *Int Forum Allergy Rhinol.* 2022;12(4):327-680. <https://doi.org/10.1002/alr.22929>
2. AlShakhs A, Almomen A, AlYaeesh I, et al. The association of smell and taste dysfunction with COVID19, and their functional impacts. *Indian J Otolaryngol Head Neck Surg.* 2021;1-6. doi:10.1007/s12070-020-02330-w
3. Otte MS, Haehner A, Bork ML, Klusmann JP, Luers JC, Hummel T. Impact of COVID-19-mediated olfactory loss on quality of life. *ORL J Otorhinolaryngol Relat Spec.* 2022;1-6. doi:10.1159/000523893
4. Bordin A, Mucignat-Caretta C, Gaudio P, et al. Comparison of self-reported symptoms and psychophysical tests in coronavirus disease 2019 (COVID-19) subjects experiencing long-term olfactory dysfunction: a 6-month follow-up study. *Int Forum Allergy Rhinol.* 2021;11(11):1592-1595. doi:10.1002/alr.22828
5. Mattos JL, Edwards C, Schlosser RJ, et al. A brief version of the questionnaire of olfactory disorders in patients with chronic rhinosinusitis. *Int Forum Allergy Rhinol.* 2019;9(10):1144-1150. doi:10.1002/alr.22392
6. Boscolo-Rizzo P, Hummel T, Hopkins C, et al. High prevalence of long-term olfactory, gustatory, and chemesthesis dysfunction in post-COVID-19 patients: a matched case-control study with one-year follow-up using a comprehensive psychophysical evaluation. *Rhinology.* 2021;59(6):517-527. doi:10.4193/Rhin21.249
7. Lloyd A. Assessment of the SF-36 version 2 in the United Kingdom. *J Epidemiol Community Health.* 1999;53(10):651-652. doi:10.1136/jech.53.10.651
8. Vaira LA, Gessa C, Deiana G, et al. The effects of persistent olfactory and gustatory dysfunctions on quality of life in long-COVID-19 patients. *Life (Basel).* 2022;12(2):141. doi:10.3390/life12020141
9. Tan HQM, Pendolino AL, Andrews PJ, Choi D. Prevalence of olfactory dysfunction and quality of life in hospitalised patients 1 year after SARS-CoV-2 infection: a cohort study. *BMJ Open.* 2022;12(1):e054598. doi:10.1136/bmjopen-2021-054598
10. Liu DT, Prem B, Sharma G, Kaiser J, Besser G, Mueller CA. Depression symptoms and olfactory-related quality of life. *Laryngoscope.* 2022. doi:10.1002/lary.30122

How to cite this article: Pendolino AL, Tan HQM, Choi D, Ottaviano G, Andrews PJ. Long-term quality-of-life impairment in patients with more than 1-year COVID-19-related olfactory dysfunction. *Int Forum Allergy Rhinol.* 2022;1-5. <https://doi.org/10.1002/alr.23071>